No abstract available.
Thrombocytosis*

No abstract available.
Thrombocytosis*

Stent thrombosis is a fatal complication in patients who have undergone percutaneous coronary intervention, and discontinuation of anti-platelet agent is a major risk factor of stent thrombosis. We report a rare case of very late stent thrombosis (VLST) following discontinuation of anti-platelet agents in a patient who experienced acute myocardial infarction and essential thrombocytosis. She had undergone implantation of a drug eluting stent (DES) and a bare metal stent (BMS) two and half years prior to her presentation. VLST developed in DES, not in BMS, following interruption of anti-platelet therapy.
Drug-Eluting Stents ; Humans ; Myocardial Infarction ; Percutaneous Coronary Intervention ; Risk Factors ; Stents ; Thrombocythemia, Essential ; Thrombocytosis ; Thrombosis

Essential thrombocythemia is a myeloproliferative disorder, characterized by marked thrombocytosis and marrow megakaryocytic hyperplasia. Although the major causes of morbidity and mortality are bleeding and thromboembolic events, the long-term prognosis is favorable and leukemic transformation is rare. We report a case of acute leukemia following treatment of Philadelphia chromosome-negative essential thrombocythemia with hydroxyurea for 4 years with a brief review of literature.
Bone Marrow ; Hemorrhage ; Hydroxyurea* ; Hyperplasia ; Leukemia ; Mortality ; Myeloproliferative Disorders ; Prognosis ; Thrombocythemia, Essential* ; Thrombocytosis

PURPOSE: Thrombocytosis has been reported in many types of malignancies and it has been studied as a prognostic factor. To better define the relationship between the platelet count and survival, we performed a retrospective analysis of patients with thrombocytosis and renal cell carcinoma, and some of whom had a lower survival rate than those with a normal platelet count. MATERIALS AND METHODS: We reviewed the medical records of patients with renal cell carcinoma and who had undergone radical nephrectomy between January, 1995 and December, 2004. A total of 112 patients were treated by radical nephrectomy for renal cell carcinoma. Among them, 67 patients without primary thrombocytosis, no familial history of renal cell carcinoma and no history of adjuvant therapy were enrolled in this study. The patients were divided into a normal platelet count group and a thrombocytosis group(greater than 400,000/microliter) according to the peri-operative platelet count. The two groups were compared pathologically and clinically, including comparing the prognosis. RESULTS: The mean follow-up was 55.8 months(range: 21 to 80). Thrombocytosis was present in 19 patients. The mean survival for the normal platelet count group was 67.8+/-39.36 months, compared with 41.4+/-30.65 months for the thrombocytosis group(p<0.05). The difference of survival between the 2 groups remained significant when controlling for the established prognostic indicators like the pathological stage, nuclear grade and cell types. CONCLUSIONS: This study documents the association of thrombocytosis with decreased survival in patients with renal cell carcinoma. The peri-operative platelet count appears to be a significant independent predictor for determining the prognosis for patients with renal cell carcinoma.
Carcinoma, Renal Cell* ; Follow-Up Studies ; Humans ; Medical Records ; Nephrectomy ; Platelet Count ; Prognosis* ; Retrospective Studies ; Survival Rate ; Thrombocythemia, Essential ; Thrombocytosis*

Gouty arthritis is a metabolic disorder characterized by hyperuricemia, deposition of monosodium urate crystal in the joints, and recurrent episodes of acute inflammatory arthritis. Depending on the actual causes of hyperuricemia, gout is classified as primary or secondary gout. In myeloproliferative neoplasms, a turnover of nucleic acids is greatly augmented and therefore the blood concentration of uric acid may be markedly increased. But an acute attack of gout is extremely rare in patients with myeloproliferative neoplasms. Essential thrombocythemia, one of the myeloproliferative neoplasms, is characterized by megakaryocytic hyperplasia in bone marrow and marked thrombocytosis. We report a case of secondary gout in a 66-year-old man with essential thrombocythemia.
Aged ; Arthritis ; Arthritis, Gouty ; Bone Marrow ; Gout ; Humans ; Hyperplasia ; Hyperuricemia ; Joints ; Nucleic Acids ; Thrombocythemia, Essential ; Thrombocytosis ; Uric Acid

Behcet's disease (BD) is a chronic inflammatory disorder characterized by vasculitis of unknown cause and involving multiple organs. Its pathogenesis includes neutrophil hyperfunction and the overproduction of inflammatory cytokines, including INF.alpha. BD is often accompanied by leukocytosis, but is rarely associated with myeloproliferative disease. Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by marked thrombocytosis and marrow megakaryocytic hyperplasia. Only one case of ET associated with incomplete.type intestinal BD during hydroxyurea treatment has been reported. Here, we report a case of essential thrombocythemia in 53.year.old female with BD who had taken no medication. Based on the history, physical examination, and routine laboratory and bone marrow examination, we diagnosed her with ET.
Bone Marrow ; Bone Marrow Examination ; Cytokines ; Female ; Humans ; Hydroxyurea ; Hyperplasia ; Leukocytosis ; Myeloproliferative Disorders ; Neutrophils ; Physical Examination ; Thrombocythemia, Essential ; Thrombocytosis ; Vasculitis

Essential thrombocythemia (ET) is a clonal stem cell disease characterized by isolated thrombocytosis and thrombohemorrhagic complications. We describe an unusual case of ET primarly presenting with skin symptoms including erythromelalgia and livedo reticularis (racemosa-type). Persistent thrombocytosis, bone marrow findings, JAK2 gene mutation, and markedly decreased ristocetin-cofactor activity were consistent with the diagnosis of ET and acquired von Willebrand disease. Elevated antiphospholipid antibodies were also found. The present case highlights the complex nature and diagnostic challenge of myeloproliferative disorders such as ET, which can involve multiple organ systems and often shows a variety of microvascular complications, coagulation anomalies, and autoimmune phenomena.
Antibodies ; Antibodies, Antiphospholipid ; Bone Marrow ; Erythromelalgia ; Humans ; Livedo Reticularis ; Myeloproliferative Disorders ; Skin ; Stem Cells ; Thrombocythemia, Essential ; Thrombocytosis ; von Willebrand Diseases

No abstract available.
Leiomyoma* ; Thrombocytosis*

No abstract available.
Humans ; Thrombocytosis